Detection of somatic mutations and HPV in the saliva and plasma of @entity1 with XXXX .

@entity1 @entity1697 @entity5 @entity1082 @entity213
To explore the potential of @entity5 -specific DNA as a biomarker for @entity213 ( @entity213 ), we queried DNA from saliva or plasma of 93 @entity213 @entity1 . We searched for somatic mutations or @entity1082 genes, collectively referred to as @entity5 DNA. When both plasma and saliva were tested, @entity5 DNA was detected in 96% of 47 @entity1 . The fractions of @entity1 with detectable @entity5 DNA in early- and late-stage disease were 100% (n = 10) and 95% (n = 37), respectively. When segregated by site, @entity5 DNA was detected in 100% (n = 15), 91% (n = 22), 100% (n = 7), and 100% (n = 3) of @entity1 with @entity5 of the oral cavity, oropharynx, larynx, and hypopharynx, respectively. In saliva, @entity5 DNA was found in 100% of @entity1 with @entity1697 and in 47 to 70% of @entity1 with @entity5 of the other sites. In plasma, @entity5 DNA was found in 80% of @entity1 with @entity1697 , and in 86 to 100% of @entity1 with @entity5 of the other sites. Thus, saliva is preferentially enriched for @entity5 DNA from the oral cavity, whereas plasma is preferentially enriched for @entity5 DNA from the other sites. Tumor DNA in saliva was found postsurgically in three @entity1 before clinical diagnosis of recurrence, but in none of the five @entity1 without recurrence. Tumor DNA in the saliva and plasma appears to be a potentially valuable biomarker for detection of @entity213 .
